You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pre-Clinical Assessment of a Minimally Invasive Meniscus Implant to Delay Arthritis

    SBC: ORTHOPRESERVE LLC            Topic: NIAMS

    Abstract Meniscus tears are among the most common orthopedic injuries, with about 1 million occurring in the United States each year and growing at a rate of 5% annually. Shortcomings associated with the current standard of care leaves a clinical need for a new treatment option. The meniscal tissue can only be repaired in limited cases due to its healing capacity, so the most common treatment for ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis

    SBC: Biotherapeutics, Inc.            Topic: NIAMS

    A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis BioTherapeutics Inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the development of novel product candidates for precision immunology. An unmet clinical need for safer, more effective drugs for plaque psoriasis remai ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Feasibility of app-delivered circadian synchronization therapy with light in a cohort of pregnant women

    SBC: ARCASCOPE INC.            Topic: NICHD

    PROJECT SUMMARY Circadian rhythms play a vital role in promoting maternal health and managing pregnancy outcomes, including gestational diabetes, preterm birth, and postpartum depression. However, interventions to mitigate circadian rhythms disruption during pregnancy are lacking, despite readily available non-pharmacological circadian interventions. The circadian timekeeping system is strengthene ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. An mHealth Approach to Decreasing Opioid Abuse and Other Diseases of Despair in Rural Populations

    SBC: ISA ASSOCIATES INC            Topic: NIDA

    Project Summary/AbstractRural Americans face numerous health disparities compared to their urban counterparts and are more likely to die from chronic health conditions, including substance abuse. Indeed, opioid-related mortality is highest in certain rural areas of the U.S., including Appalachia, New England, and the mountain west. A number of studies looking at morbidity and mortality provide ins ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage

    SBC: THE TINY CARGO COMPANY            Topic: 102

    Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects of cancer radiation therapy (RT). Our therapeutic is comprised of milk-derived extracellular vesicles (mEVs) loaded with a safe and highly effective radioprotective drug – a formulation that we call Milactatm. RT compli ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Sprayable Hydrogel Barrier for the Delivery of Adhesion-Preventing Therapeutics

    SBC: LUNA LABS USA LLC            Topic: 300

    ABSTRACT Adhesion formation after intra-abdominal surgery poses a significant health risk, cited as a leading cause of small bowel obstruction and female infertility. Methods to prevent these adhesions are currently limited to barrier films, which are difficult to place and are often restricted to use preventing adhesions to the surgical incision site, leaving the bulk of the abdominal contents un ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A nanoengineering platform for programmable gene editing therapies against rare diseases

    SBC: PARABON NANOLABS, INC.            Topic: 300

    PROJECT SUMMARY More than 300 million people worldwide are affected by a genetic health condition. Over 4,400 genetic diseases have been identified; nearly all of which are considered rare, which limits the amount of research each receives. Gene therapy is an attractive approach for treatment of genetic disease because of its versatility and broad applicability. Genome editing systems such as CRIS ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SPNS2 inhibitors as renal fibrosis therapy

    SBC: Flux Therapeutics, LLC            Topic: 400

    Fibrosis is an aberrant wound healing process characterized by progressive accumulation of extracellular matrix that ultimately destroys organ function. Progressive fibrosis is inherent to chronic kidney disease (CKD), which often leads to end-stage renal disease. Although patients can be maintained by hemodialysis while awaiting transplantation, their’s and their care-giver’s quality of life ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Coronary Artery Vasodilator Development

    SBC: COEURATIVE INC            Topic: NHLBI

    PROJECT SUMMARY: Cardiovascular diseases (CVD) are the leading cause of death globally, and are responsible for 1 in 3 deaths in the US. It is estimated that between 2015 and 2018, ~127 million US adults had some form of CVD. Coronary heart disease (CHD) is directly responsible for ~41% of CVD deaths. Angina pectoris, a primary symptom of CHD, is chest pain or discomfort caused by an imbalance of ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government